After Decades of Dieting, She Finally Found Hope: A True GLP-1 Success Story

How Karen Glanz’s Weight-Loss Journey Changed the Way She Viewed Obesity, Health, and Medical Treatment

For decades, weight loss had been a frustrating cycle for Karen Glanz. She understood nutrition. She understood physical activity. In fact, she was a respected researcher whose professional work focused on obesity, nutrition, physical activity, and healthy environments. She was also an athlete who participated in triathlons, including the Ironman World Championship. Yet despite her knowledge and an active lifestyle, managing her weight remained a lifelong challenge.

Her story is compelling because it challenges one of the most persistent ideas surrounding weight loss: that people simply need to try harder. Glanz had spent years doing exactly what many weight-loss programs recommend. She exercised, followed healthy eating habits, and repeatedly worked to lose weight. She would lose some weight, regain it, and then begin the process again. Eventually, she decided to explore something she had never expected to use herself: medication for weight management.

In 2023, after discussing her health with her physician, Glanz was prescribed Wegovy, a medication containing semaglutide and belonging to the GLP-1 receptor agonist class. After an initial delay caused by availability issues, she eventually began treatment. By August 2024, she had lost 46 pounds in roughly 11 months, while maintaining her active lifestyle. She also reported improvements in her LDL cholesterol and liver-function tests.

Her experience offers a deeply personal look at what can happen when someone who has spent years trying to manage weight finally receives medical support.

Decades of Trying to Lose Weight

Glanz’s weight-loss story did not begin with GLP-1 medication. Long before Wegovy became part of her life, she had already spent years trying to control her weight through diet and physical activity.

According to her account presented to the National Academies, she experienced repeated cycles of losing weight and regaining it. Diets and high levels of physical activity would typically result in losing around five to 10 pounds, but the weight eventually returned. This repeated pattern became frustrating and emotionally difficult.

Her experience is important because she was not someone who lacked knowledge about healthy living. Her career centered on researching health behavior, nutrition, physical activity, and environments that influence people’s ability to make healthy choices. She also enjoyed being physically active and participated in demanding endurance events.

Even with that background, maintaining a lower weight remained difficult.

That reality reflects the complexity of obesity. Weight is influenced by numerous biological, behavioral, environmental, and social factors. While healthy eating and exercise remain important, they do not necessarily produce the same results for every person.

For someone who has repeatedly lost and regained weight, another diet can eventually feel less like an opportunity and more like another potential disappointment.

When Knowledge and Willpower Were Not Enough

One of the most relatable aspects of Glanz’s story is the conflict between knowing what to do and being unable to achieve the desired outcome consistently.

She had an active lifestyle and understood healthy nutrition, yet her weight continued to fluctuate. She even described feeling embarrassed about wearing swimsuits and athletic clothing despite her commitment to physical activity. She continued exercising through the ups and downs of her weight.

This emotional side of weight management is often overlooked.

People struggling with obesity may experience shame, frustration, or embarrassment even when they are making genuine efforts to improve their health. When those efforts repeatedly fail to produce lasting results, it can become easy to blame oneself.

Glanz’s experience offers another perspective. Perhaps the issue was not that she did not care enough. Perhaps the biology of weight regulation was more complicated than simply eating less and exercising more.

That realization eventually helped change her attitude toward medical treatment.

The Turning Point: Considering a GLP-1 Medication

The decision to try a GLP-1 medication came somewhat unexpectedly.

In 2023, Glanz’s primary internist recommended a statin after concerns about her cholesterol. During that conversation, she asked about GLP-1 medication for weight management. Her physician prescribed Wegovy, but obtaining the medication proved difficult because of availability.

Her prescription was initially held at a large pharmacy for more than three months. Eventually, a colleague recommended Penn Medicine’s specialty pharmacy. With her doctor’s approval, she was able to begin treatment at a 0.5-milligram dose. She started Wegovy approximately four months after the original prescription.

The delay itself illustrates another part of the modern GLP-1 story that is often overlooked. Interest in these medications has created challenges involving affordability, insurance coverage, availability, and access.

For Glanz, finally obtaining the medication marked the beginning of a very different chapter.

The Weight Started Coming Off

The results were significant.

In the first five months, Glanz reported losing 32 pounds while maintaining her high level of physical activity. By August 2024, she had lost 46 pounds in approximately 11 months. A National Academies report documenting her experience includes a graph showing her weight declining from roughly 158 pounds to 112 pounds over that period.

The change was not simply a result of becoming more active. She had already been highly active before treatment.

For Glanz, medication appeared to provide something that years of dieting and exercise had not: additional support for the biological side of weight management.

She described the medication as a “miracle drug,” a statement that reflects her personal experience rather than a guarantee for other patients. Individual responses to GLP-1 medications vary, and a person’s results depend on factors including health status, treatment plan, lifestyle, and adherence.

Still, her transformation demonstrated what became possible when medical treatment was added to an already health-conscious lifestyle.

The Health Changes Beyond the Scale

Weight loss was only one part of Glanz’s reported transformation.

While taking Wegovy alongside a statin, she experienced a significant reduction in LDL cholesterol. Her liver-function tests also returned to normal.

These changes gave her journey a broader meaning.

Instead of focusing exclusively on appearance or a target number on the scale, her experience became connected to overall health. Weight management can be particularly meaningful when it contributes to improvements in physical functioning and health markers.

Research supports the idea that semaglutide can produce clinically meaningful weight loss when used alongside lifestyle intervention. In the STEP 1 clinical trial, adults with overweight or obesity who received weekly semaglutide experienced substantially greater average weight loss over 68 weeks than those who received placebo. Participants receiving semaglutide also experienced improvements in several cardiometabolic risk factors and physical functioning.

That does not mean every patient will experience the same results as Glanz. Clinical trials provide population-level evidence, while individual stories show how treatment can feel in real life.

Why Her Story Is Different From Another Diet

Perhaps the most meaningful part of Glanz’s journey is that she did not abandon healthy habits when she started medication.

She continued to be physically active. Her years of knowledge about nutrition and health did not suddenly become irrelevant. Instead, the medication became another component of her approach to managing her weight.

This distinction is important.

GLP-1 medications are not intended to replace healthy eating or physical activity. For weight-management indications, semaglutide is used alongside a reduced-calorie diet and increased physical activity. The FDA labeling for Wegovy specifically describes it as an adjunct to these lifestyle measures.

The American College of Physicians’ 2026 living guideline likewise recommends certain medications, including semaglutide and tirzepatide, alongside lifestyle modifications for appropriate adults with obesity.

For people who have spent decades being told to simply change their diet and exercise more, this represents a major shift in perspective.

Medical treatment does not necessarily mean giving up on healthy habits. It can mean adding another tool when lifestyle changes alone have not produced sufficient results.

The Emotional Side of Weight Loss

Glanz’s journey was physical, but it was also deeply emotional.

She had spent years feeling embarrassed about her weight even while participating in physically demanding activities. The disconnect between being active and still struggling with weight could understandably be difficult.

Losing weight changed more than her measurements. It offered a sense of relief after years of repeated attempts.

That emotional component is important because weight loss is often portrayed as a simple before-and-after photograph. The reality can be much more complicated.

A person may spend years feeling judged by others or disappointed in themselves. They may avoid certain clothes, photographs, social situations, or activities because of concerns about their body.

When weight begins to change, confidence can gradually return. But the deeper transformation may be learning that needing medical support does not mean someone failed.

For Glanz, the experience helped demonstrate that obesity involves both biology and behavior. Her own story became an example of why those two factors need to be considered together.

What About Side Effects?

No GLP-1 story should present medication as completely effortless.

Semaglutide can cause side effects, particularly gastrointestinal symptoms. In the STEP 1 clinical trial, nausea and diarrhea were among the most common adverse events, and gastrointestinal symptoms led some participants to discontinue treatment.

Individual experiences vary. Some people report relatively mild or temporary symptoms, while others may have more significant difficulties.

This is why medical supervision matters. A healthcare professional can determine whether a GLP-1 medication is appropriate, monitor progress, address side effects, and make adjustments when necessary.

Glanz’s experience should therefore be viewed as one person’s documented journey, not as a prescription for anyone else.

Changing the Way We Think About Weight Loss

Perhaps the biggest lesson from this true GLP-1 success story is that weight management does not have to be framed as a battle between willpower and failure.

Glanz had the knowledge. She had the motivation. She exercised. She understood healthy eating. Yet she still experienced repeated weight regain.

Her story suggests that medical treatment can be appropriate for people who have struggled despite sustained lifestyle efforts.

That perspective can also reduce some of the shame surrounding obesity treatment. Taking medication does not erase the effort someone has already made. It can simply address another part of the problem.

The goal is not to make healthy habits unnecessary. The goal is to make long-term health more achievable.

Nutrition Still Matters During a GLP-1 Journey

One potential challenge with appetite-reducing medications is making sure that the foods a person does eat provide enough nutrition.

When appetite decreases, nutrient-dense meals become especially important. Protein, vegetables, fruits, whole grains, healthy fats, and adequate fluids can help support overall nutrition.

Convenient protein-rich options can also be useful for people trying to maintain balanced nutrition during a weight-management journey. Products such as Skinii can fit into that broader wellness approach, but they should complement rather than replace a varied, nutrient-rich diet.

The emphasis should remain on nourishing the body rather than simply eating as little as possible.

What Her Story Teaches About Sustainable Weight Management

Glanz’s story offers a lesson that applies far beyond GLP-1 medications: sometimes success requires changing the strategy rather than blaming yourself for the previous strategy not working.

After decades of dieting and repeated weight regain, she finally found an approach that worked differently for her.

Her experience does not mean that everyone needs a GLP-1 medication. These treatments have specific indications, potential side effects, costs, access considerations, and medical considerations. Anyone considering them should discuss the decision with a qualified healthcare professional.

But her journey does challenge the outdated idea that people who struggle with obesity simply need more discipline.

She had spent years demonstrating discipline. Her story shows that weight management can be complicated even for people who understand nutrition and exercise exceptionally well.

Finding Hope After Years of Trying

After decades of dieting, Karen Glanz’s story ultimately became a story about hope.

The 46 pounds she lost were significant, but the larger transformation was the shift in how she understood her own struggle. She discovered that medical treatment could become part of a comprehensive approach to weight management rather than something to feel ashamed about.

Her experience also demonstrates that a successful weight-loss journey does not have to begin with another restrictive diet. Sometimes it begins with a conversation with a doctor and an honest acknowledgment that previous strategies have not been enough.

For people who have spent years losing and regaining weight, that realization can be powerful.

Weight loss is not a test of character. It is a health journey, and different people may need different tools to navigate it. For some, lifestyle changes may be enough. For others, medical treatment may become an important part of the solution.

Karen Glanz’s journey shows that asking for help does not mean giving up. Sometimes, it is the step that finally makes lasting change feel possible.

Sources and Further Reading

• National Academies of Sciences, Engineering, and Medicine — Karen Glanz’s lived experience with GLP-1 treatment: Read the National Academies report
• National Academies / NCBI Bookshelf — Karen Glanz’s Wegovy weight-loss experience: Read the documented patient story
• JAMA — STEP 3 semaglutide clinical trial: Read the clinical research
• FDA — Wegovy prescribing information: Read the FDA information
• American College of Physicians — 2026 obesity medication guideline: Read the updated guideline information

Note: Karen Glanz’s results are her personal experience and should not be interpreted as typical or guaranteed results. GLP-1 medications should be used under appropriate medical supervision.